Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients

Zhu, Linhui; Li, Huan; Du, Qin; Ye, Xuan; Yu, Sijia; Luo, Xin; Zhai, Qian

doi:10.1007/s10147-021-02034-3

Cited by 6 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxaliplatin was more likely to cause allergic reactions ( 29 ), and the hypersensitivity and Type I hypersensitivity are particularly evident from the data in this paper. Some scholars have proposed Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening ( 5 ).…”

Section: Discussionmentioning

confidence: 62%

“…As shown in Table 6, the association of PTs, such as nausea and vomiting, with carboplatin and oxaliplatin was low (no signal detected), but this does not mean that the incidence of adverse events was low [14]. Carboplatin can be used instead of cisplatin or oxaliplatin when formulating chemotherapy regimens, thereby reducing the risk of gastrointestinal reactions in patients [15,21,29].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data

Feng

Zhou²,

Chen³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundWith the widespread application of platinum drugs in antitumor therapy, the incidence of platinum drug adverse events (ADEs) is always severe. This study aimed to explore the adverse event signals of Cisplatin, Carboplatin and Oxaliplatin, three widely used platinum-containing drugs, and to provide a reference for rational individualized clinical drug use.MethodsThe adverse event report data of the three platinum drugs from the first quarter of 2017 to the fourth quarter of 2021 were extracted from the FAERS database, and the data mining and risk factors for the relevant reports were carried out using the reporting odds ratio (ROR) method the proportional reporting ratio (PRR)and the comprehensive criteria (MHRA) method.ResultsA total of 1853 effective adverse event signals were obtained for the three platinum agents, including 558 effective signals for Cisplatin, 896 effective signals for Carboplatin, and 399 effective signals for Oxaliplatin. The signals involve 23 effective different system organs (SOCs). The adverse events of Cisplatin are mainly fixed on blood and lymphatic system diseases, gastrointestinal diseases, systemic diseases and various reactions at the administration site. The adverse events of Carboplatin are mainly focused on blood and lymphatic system diseases, respiratory system, thoracic and mediastinal diseases, while the adverse events of Oxaliplatin are mainly concentrated in respiratory system, thoracic and mediastinal diseases, various nervous system diseases, and gastrointestinal system diseases.ConclusionIt was found that the main systems involved in common adverse events of platinum drugs are different, and the correlation strength of platinum drugs with the certain adverse events of each system is different.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data

Feng

Zhou²,

Chen³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…These 2 cases support the findings reported by Gamelin et al Wheezing was due to pseudolaryngospasm and not anaphylaxis. Furthermore, Zhu et al [6] reported that the risk factors for oxaliplatin hypersensitivity reactions include a history of use of platinum-based drugs, allergy, prolonged periods of oxaliplatin withdrawal, and less than 12 mg of premedication with dexamethasone prior to chemotherapy. Dexamethasone has been shown to increase the area under the concentration-time curve approximately twofold when combined with aprepitant [7]; in these 2 patients, the premedication was 6.6 mg of dexamethasone, but the area under the concentration-time curve was thought to be equivalent to that of the 13.2 mg dose.…”

Section: Discussionmentioning

confidence: 99%

Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports

Kawaguchi¹,

Aoyama²,

Tsuneki³

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

Oxaliplatin is a key drug for colorectal cancer and causes peripheral neuropathy. Oxaliplatin-induced laryngopharyngeal dysesthesia is an acute peripheral neuropathy similar to a hypersensitivity reaction. Hypersensitivity reactions to oxaliplatin do not require immediate discontinuation, but re-challenge and desensitization therapy can be very burdensome for patients. We encountered 2 cases in which laryngopharyngeal dysesthesia could be differentiated from hypersensitivity reactions to oxaliplatin, and treatment could continue. The first case was that of a 58-year-old woman who developed dyspnea during the first course of combination therapy with capecitabine and oxaliplatin as the primary treatment for advanced rectal cancer. After laryngopharyngeal dysesthesia was differentiated from hypersensitivity reaction based on these typical symptoms, she was considered to have grade 3 (Common Terminology Criteria for Adverse Events [CTCAE] ver. 5) laryngopharyngeal dysesthesia. The second course of oxaliplatin was extended from 2 to 4 h, but symptoms recurred. The third course was performed with a reduced dose of oxaliplatin from 130 mg/m2 to 100 mg/m2, and the patient could complete the treatment without symptom recurrence. The second case involved a 76-year-old woman who developed grade 3 laryngopharyngeal dysesthesia during the first course of combination therapy with capecitabine and oxaliplatin as the primary treatment for localized colon cancer. Based on the experience of the first case, we reduced the oxaliplatin dose from 130 mg/m2 to 100 mg/m2 for the second course, and the patient completed the treatment without symptoms. This dose reduction was effective for grade 3 laryngopharyngeal dysesthesia caused by oxaliplatin without reducing therapeutic efficacy.

show abstract

“…The Korean Journal of Gastroenterology The pathophysiology and mechanisms underlying HSR remain unclear; however, immediate-type HSRs secondary to oxaliplatin use are attributable to immunoglobulin (Ig)E-mediated type I hypersensitivity. 15 In one case report, there was an increase in serum tryptase levels and a positive intradermal skin test (IDT) to leucovorin. 6 Also, specific IgE antibodies were detected in patients who experienced HSR after leucovorin administration, suggesting that leucovorin-induced HSR is mediated by IgE allergic reactions.…”

Section: Discussionmentioning

confidence: 99%

Leucovorin-induced Hypersensitivity Reaction in a Patient with Metastatic Colorectal Cancer Treated with Cetuximab Plus FOLFOX Chemotherapy: A Case Report

Kim,

Lee

et al. 2023

Korean J Gastroenterol

View full text Add to dashboard Cite

The FOLFOX regimen (combination of leucovorin, 5-fluorouracil, and oxaliplatin) is the first-line treatment for high-risk stage 2 and 3 colorectal cancer patients. While hypersensitivity reactions (HSRs) caused by oxaliplatin are commonly reported, HSRs due to leucovorin have been infrequently reported. This report aims to investigate the clinical presentation, diagnosis, and management of leucovorin induced HSRs. A 60-year-old female developed generalized edema, dyspnea, and facial redness during cetuximab plus FOLFOX chemotherapy administered for management of metastatic colorectal cancer. Because HSRs induced by oxaliplatin are commonly reported, we initially presumed an oxaliplatin-induced HSR. However, despite undergoing oxaliplatin desensitization, HSRs persisted, and they were still observed when leucovorin was administered without oxaliplatin. The patient was diagnosed with leucovorin-induced HSR and underwent leucovorin desensitization. However, the reactions recurred within 30 minutes of the initiating the desensitization. Considering unsuccessful leucovorin desensitization, leucovorin was excluded. The patient received cetuximab and oxaliplatin chemotherapy without leucovorin to date without any adverse effects. While leucovorin-induced HSRs are infrequently reported, they should still be regarded as potential adverse effects.

show abstract

Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients

Cited by 6 publications

References 44 publications

Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data

Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data

Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports

Leucovorin-induced Hypersensitivity Reaction in a Patient with Metastatic Colorectal Cancer Treated with Cetuximab Plus FOLFOX Chemotherapy: A Case Report

Contact Info

Product

Resources

About